USA: Generic Oral Solids and Dermatology Novartis’ Sandoz Terminates Sale Agreement with Aurobindo Pharma
Sandoz has called off the sale of its US generic oral solids and dermatology businesses to Aurobindo Pharma USA after the pharma company failed to make the transaction within the anticipated timelines.
Basel/Switzerland – Novartis has recently announced that the mutual agreement to sell the Sandoz US generic oral solids and dermatology businesses to Aurobindo Pharma USA has been terminated. This decision was taken as approval from the U.S. Federal Trade Commission as the transaction was not obtained within anticipated timelines.
Sandoz will continue to operate its oral solids and dermatology business as part of the Sandoz US business.